.png)
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have become a normative therapy in medicine. By mimicking the glucagon-like peptide-1 hormone, these medications slow gastric emptying, suppress appetite, and reduce food intake dramatically. While the weight loss results can be impressive, the sharp reduction in calories consumed comes with a significant and underappreciated consequence: the body is frequently deprived of the protein, vitamins, and minerals it needs to function well. As millions of adults now use these medications long-term, understanding the nutritional trade-offs has become essential.
The most celebrated feature of GLP-1 drugs is also the root of their nutritional risk. By powerfully blunting hunger signals, these medications can reduce daily caloric intake by 30–50%. When people eat significantly less overall, they tend to eat less of everything — including nutrient-dense foods like lean meats, legumes, dairy, leafy greens, and whole grains. The result is a caloric deficit that often outpaces any deliberate dietary planning. Unlike a structured, supervised diet that prioritizes nutritional adequacy, appetite suppression driven by medication does not discriminate: it simply makes people want less food, regardless of its quality or completeness.
The scope of nutritional depletion on GLP-1 drugs is no longer speculative — it is now backed by real-world evidence at a massive scale. A landmark study by Butsch and colleagues, published in Obesity Pillars in 2025, examined the medical records of 461,382 adults who were newly prescribed GLP-1 receptor agonists between 2017 and 2021, none of whom had prior diagnoses of nutritional deficiencies. The results were striking. Nearly 13% of patients were diagnosed with nutritional deficiencies after just six months on GLP-1 therapy, and over 22% were diagnosed within twelve months — more than one in five adults developing a measurable deficiency within a single year. The study's authors concluded that these findings highlight the critical importance of nutritional screening and the inclusion of dietitians and physician nutrition specialists in the care of patients on GLP-1 medications. Importantly, the data also showed that patients who had a dietitian visit within the first six months of starting GLP-1 therapy were more likely to have deficiencies recorded and addressed — underscoring how often nutritional problems go undetected without proactive monitoring. This is why I like to keep tabs on patients blood levels of key nutrients while they are on these drugs.
Among all the nutritional risks associated with GLP-1 medications, inadequate protein intake is arguably the most consequential. When the body loses weight rapidly and does not receive sufficient dietary protein — generally recommended at 1.2 to 1.6 grams per kilogram of body weight during active weight loss — it begins breaking down lean muscle mass to meet its amino acid needs. Research has shown that a notable proportion of weight lost on GLP-1 drugs can be lean mass rather than fat alone, particularly in older adults. A 2023 analysis published in Diabetes, Obesity and Metabolism found that participants on semaglutide lost significant amounts of lean body mass alongside fat, raising concern about long-term muscle integrity, bone density, and metabolic rate. Sarcopenia — the progressive loss of muscle — carries serious downstream health risks including frailty, falls, and reduced quality of life.
Beyond protein, GLP-1 drugs create conditions ripe for micronutrient depletion. The slowing of gastric emptying affects how efficiently the stomach processes and absorbs nutrients. Intrinsic factor — a protein secreted by the stomach lining that is essential for vitamin B12 absorption — may be produced in lower quantities when gastric activity is reduced. B12 deficiency develops quietly over months and can result in fatigue, nerve damage, cognitive impairment, and anemia. Iron absorption, which is acid-dependent and occurs primarily in the upper small intestine, is similarly vulnerable when food transit slows and stomach acid production is altered. Zinc, which is critical for immune function, wound healing, and hormone regulation, is frequently low in people eating restrictive or highly processed diets — a pattern common among GLP-1 users who gravitate toward small, soft, or liquid foods that are easier to tolerate.
Vitamins A, D, E, and K are fat-soluble, meaning they require adequate dietary fat for absorption. When overall food intake falls and the variety of foods consumed narrows, these vitamins are often the first to fall short. Vitamin D insufficiency is already widespread in the general adult population; GLP-1-driven dietary restriction can deepen that deficit significantly. Since vitamin D works in concert with calcium and magnesium to maintain bone density, inadequate intake of all three creates a pathway toward accelerated bone loss — particularly dangerous in postmenopausal women and older men who are already at elevated risk. Some clinical endocrinologists have begun monitoring bone density scans in long-term GLP-1 users for precisely this reason, recognizing that rapid weight loss is a known risk factor for bone resorption.
GLP-1 drugs frequently cause nausea, vomiting, and diarrhea, especially during dose escalation. These gastrointestinal side effects compound the nutritional picture substantially. Repeated vomiting and loose stools deplete electrolytes including potassium, sodium, and magnesium at an accelerated rate. Magnesium in particular is essential for over 300 processes in the body, including muscle contraction, blood pressure regulation, and blood sugar control. Low magnesium levels are associated with muscle cramps, heart arrhythmias, anxiety, and poor sleep. In people already eating less food and experiencing digestive disturbances, maintaining electrolyte balance without deliberate supplementation becomes extremely difficult.
Certain adults are significantly more vulnerable to nutrient depletion on GLP-1 medications. Adults over 60 are at heightened risk because aging already reduces the body's efficiency at absorbing several nutrients, and they have less muscle reserve to begin with. Postmenopausal women face compounding bone health risks. People who enter treatment with existing nutritional deficiencies — which are common in individuals with obesity, type 2 diabetes, and metabolic syndrome — may see those deficiencies worsen rapidly once caloric intake drops. Additionally, individuals who adopt very restrictive eating patterns (tiny portions, liquid meals, avoidance of high-protein foods due to nausea) without professional dietary guidance are at particular risk of developing clinically significant deficiencies within six to twelve months of starting treatment.
Awareness and proactive planning can substantially reduce these nutritional risks. If you are using one of these medications then prioritize protein at every meal, aiming for 25 or so grams per meal, focusing on high-quality sources like eggs, Greek yogurt, cottage cheese, fish, and poultry. Some of he supplements we commonly recommend from the Stengler Center include:
Moreover, resistance exercise is strongly recommended to preserve lean muscle mass during active weight loss. The goal is not to undermine the medication's benefits — which are real and clinically meaningful — but to ensure that the body losing weight does so in a way that preserves long-term strength, function, and vitality.
Butsch, W.S., Sulo, S., Chang, A.T., Kim, J.A., Kerr, K.W., Williams, D.R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S.B. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity Pillars, 15, 100186. https://doi.org/10.1016/j.obpill.2025.100186
Blundell, J., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, energy expenditure, gastric emptying, and body composition in obesity. Diabetes, Obesity and Metabolism, 19(9), 1242–1251.
Christoffersen, B.Ø., et al. (2023). Lean mass changes in semaglutide-treated patients: Implications for body composition monitoring. Diabetes, Obesity and Metabolism, 25(7), 1877–1886.
Kushner, R.F., et al. (2023). Semaglutide 2.4 mg and changes in lean body mass: secondary analysis from the STEP trials. Obesity, 31(3), 640–649.
Rubino, D.M., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity. JAMA, 327(2), 138–150.
Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
